Emerging Therapeutic Targets for Platinum-Resistant Ovarian Cancer.

Recurrent platinum-resistant ovarian cancer represents a significant therapeutic challenge, characterized by poor responses to standard chemotherapy and limited survival outcomes. This chapter comprehensively reviews the biological mechanisms underlying platinum resistance, including alterations in DNA repair pathways, intracellular drug transport, evasion of apoptosis, tumor microenvironment adaptations, and cancer stem cell dynamics. Emerging therapies targeting these mechanisms are discussed in detail, along with promising strategies that combine these therapies. Clinical trial data are discussed to highlight advances in overcoming platinum resistance and the potential for biomarker-driven treatment approaches. The chapter emphasizes the importance of targeting tumor heterogeneity and resistance mechanisms through novel therapies and personalized strategies to improve outcomes in patients with recurrent platinum-resistant ovarian cancer.